Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection
- PMID: 32937764
- PMCID: PMC7563117
- DOI: 10.3390/vaccines8030526
Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection
Abstract
The congenital transmission of cytomegalovirus (cCMV) is the most common infectious cause of disability in children in the developed world, and probably globally [...].
Conflict of interest statement
M.R.S. reports receipt of consulting fees from Moderna Vaccines. D.J.D. reports consulting fees, research funding, and stock ownership in Helocyte, Inc.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources